Atsushi Yoshida1, Katsuyoshi Matsuoka2, Fumiaki Ueno1, Toshio Morizane1, Yutaka Endo1, Toshifumi Hibi3. 1. Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Japan. 2. Department of Gastroenterology and Hepatology, Toho University Sakura Medical Center, Chiba, Japan. 3. Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan.
Abstract
BACKGROUND: Anti-tumor necrosis factor-α (TNF-α) agents are effective for moderately to severely active ulcerative colitis (UC). Nonetheless, a proportion of patients fail to respond to these agents as therapy for induction of remission. Recent studies indicated that perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) may predict response to anti-TNF-α agents in UC patients. However, whether PR3-ANCA can predict primary nonresponse (PNR) to anti-TNF-α agents has not yet been evaluated. The aim of this study was to examine whether PR3-ANCA can predict PNR to anti-TNF-α in UC patients. METHODS: This was a single-center retrospective study. Data were extracted from 50 patients with UC who had measurements of PR3-ANCA and received anti-TNF-α agents for the first time as induction therapy. The primary endpoint of this study was a proportion of patients with PNR stratified by PR3-ANCA positivity. PNR to anti-TNF-α agents was defined as failure to achieve reduction in partial Mayo score by 2 or more points and change to other therapeutics within 6 weeks. RESULTS: Fourteen (28%) of the 50 patients were PR3-ANCA positive. Seventeen (34%) of the 50 patients demonstrated PNR. Eleven (78.6%) of the 14 PR3-ANCA-positive patients demonstrated PNR, while 6 (16.7%) of the 36 PR3-ANCA-negative patients demonstrated PNR. Multivariate analysis demonstrated that PR3-ANCA positivity was associated with PNR to anti-TNF-α agents (odds ratio 19.29, 95% CI: 3.30-172.67; p = 0.002). CONCLUSION: PR3-ANCA positivity can predict PNR to anti-TNF-α agents in UC patients.
BACKGROUND: Anti-tumor necrosis factor-α (TNF-α) agents are effective for moderately to severely active ulcerative colitis (UC). Nonetheless, a proportion of patients fail to respond to these agents as therapy for induction of remission. Recent studies indicated that perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) may predict response to anti-TNF-α agents in UC patients. However, whether PR3-ANCA can predict primary nonresponse (PNR) to anti-TNF-α agents has not yet been evaluated. The aim of this study was to examine whether PR3-ANCA can predict PNR to anti-TNF-α in UC patients. METHODS: This was a single-center retrospective study. Data were extracted from 50 patients with UC who had measurements of PR3-ANCA and received anti-TNF-α agents for the first time as induction therapy. The primary endpoint of this study was a proportion of patients with PNR stratified by PR3-ANCA positivity. PNR to anti-TNF-α agents was defined as failure to achieve reduction in partial Mayo score by 2 or more points and change to other therapeutics within 6 weeks. RESULTS: Fourteen (28%) of the 50 patients were PR3-ANCA positive. Seventeen (34%) of the 50 patients demonstrated PNR. Eleven (78.6%) of the 14 PR3-ANCA-positive patients demonstrated PNR, while 6 (16.7%) of the 36 PR3-ANCA-negative patients demonstrated PNR. Multivariate analysis demonstrated that PR3-ANCA positivity was associated with PNR to anti-TNF-α agents (odds ratio 19.29, 95% CI: 3.30-172.67; p = 0.002). CONCLUSION: PR3-ANCA positivity can predict PNR to anti-TNF-α agents in UC patients.
Authors: Marc Ferrante; Séverine Vermeire; Konstantinos H Katsanos; Maja Noman; Gert Van Assche; Fabian Schnitzler; Ingrid Arijs; Gert De Hertogh; Ilse Hoffman; J Karel Geboes; Paul Rutgeerts Journal: Inflamm Bowel Dis Date: 2007-02 Impact factor: 5.325
Authors: Matthias Jürgens; Rüdiger P Laubender; Franziska Hartl; Maria Weidinger; Julia Seiderer; Johanna Wagner; Martin Wetzke; Florian Beigel; Simone Pfennig; Johannes Stallhofer; Fabian Schnitzler; Cornelia Tillack; Peter Lohse; Burkhard Göke; Jürgen Glas; Thomas Ochsenkühn; Stephan Brand Journal: Am J Gastroenterol Date: 2010-03-02 Impact factor: 10.864
Authors: Maria Theresa Arias; Niels Vande Casteele; Séverine Vermeire; Anthony de Buck van Overstraeten; Thomas Billiet; Filip Baert; Albert Wolthuis; Gert Van Assche; Maja Noman; Ilse Hoffman; Andre D'Hoore; Ann Gils; Paul Rutgeerts; Marc Ferrante Journal: Clin Gastroenterol Hepatol Date: 2014-08-10 Impact factor: 11.382
Authors: George E Reese; Vasilis A Constantinides; Constantinos Simillis; Ara W Darzi; Timothy R Orchard; Victor W Fazio; Paris P Tekkis Journal: Am J Gastroenterol Date: 2006-09-04 Impact factor: 10.864